Acura Pharmaceuticals to Host Third Quarter 2015 Financial Results Conference Call on November 5, 2015

PALATINE, IL -- (Marketwired) -- 10/28/15 --

Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the Company plans to report financial results for third quarter 2015 following the close of financial markets on Wednesday, November 4, 2015. The Company will host a conference call to discuss the results on Thursday, November 5, 2015 at 8:30 a.m. ET.

To participate in the live conference call, please dial 888-572-7034 (U.S. and Canada) five to ten minutes prior to the start of the call. The participant passcode is 402784.

A replay of the call will be available beginning November 5, 2015 and ending on November 26, 2015 on the company's website, and by dialing 888-203-1112 (U.S. and Canada). The replay participant code is 402784.

About Acura Pharmaceuticals

Acura Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development and commercialization of product candidates intended to address medication abuse and misuse, utilizing its proprietary LIMITX™, AVERSION® and IMPEDE® Technologies. LIMITX contains ingredients that are intended to reduce or limit the rate or extent of opioid release when multiple tablets are ingested. AVERSION contains polymers that cause the drug to gel when dissolved; it also contains compounds that irritate the nasal passages if the product is snorted. IMPEDE is designed to disrupt the processing of pseudoephedrine from tablets into methamphetamine.

   Contact:for Acura Investor RelationsEmail contact847-705-7709Renmark Financial Communications Inc. Robert Thaemlitz: Email contactLaura Welsh: Email contact(416) 644-2020 or (514) 939-3989 Email contact

Source: Acura Pharmaceuticals, Inc.

You May Also Be Interested In

• Growth isn't weak enough to truly undercut inflation pressures - BMO
• Warren Buffet's Berkshire stock target raised at UBS into earnings
• PayPal (PYPL) stock: Risk-reward 'finally looks favorable' says Deutsche Bank